Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ex-Superpharm exec Muhammad Mannan

Executive Summary

Former R&D manager is permanently debarred by an FDA order published in the April 6 Federal Register after failing to request a hearing. In May 1992, Mannan was sentenced to two years imprisonment, with all but four months suspended for making false submissions to FDA in Superpharm ANDAs. FDA proposes to debar ex-Bolar (now Circa) CEO Robert Shulman and ex-Quad VP-Regulatory Affairs Jan Sturm.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022422

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel